Fmr LLC Acquires 10,017 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

FMR LLC raised its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 3.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 290,861 shares of the company's stock after purchasing an additional 10,017 shares during the period. FMR LLC owned about 0.36% of IDEXX Laboratories worth $146,949,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also made changes to their positions in IDXX. Eads & Heald Wealth Management boosted its stake in shares of IDEXX Laboratories by 0.8% in the second quarter. Eads & Heald Wealth Management now owns 2,686 shares of the company's stock valued at $1,309,000 after buying an additional 22 shares in the last quarter. LRI Investments LLC boosted its holdings in IDEXX Laboratories by 21.7% in the second quarter. LRI Investments LLC now owns 129 shares of the company's stock valued at $63,000 after purchasing an additional 23 shares during the last quarter. Sovereign Financial Group Inc. raised its stake in IDEXX Laboratories by 5.1% during the third quarter. Sovereign Financial Group Inc. now owns 470 shares of the company's stock valued at $237,000 after buying an additional 23 shares in the last quarter. Mather Group LLC. lifted its holdings in shares of IDEXX Laboratories by 3.9% in the 3rd quarter. Mather Group LLC. now owns 617 shares of the company's stock worth $312,000 after purchasing an additional 23 shares during the last quarter. Finally, Angeles Wealth Management LLC raised its stake in IDEXX Laboratories by 2.4% during the 3rd quarter. Angeles Wealth Management LLC now owns 1,078 shares of the company's stock valued at $545,000 after acquiring an additional 25 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the company's stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the transaction, the director now directly owns 905 shares in the company, valued at $380,498.20. This represents a 27.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 2.18% of the company's stock.

IDEXX Laboratories Price Performance

NASDAQ IDXX traded up $2.32 on Wednesday, hitting $434.43. The stock had a trading volume of 1,303,295 shares, compared to its average volume of 511,002. IDEXX Laboratories, Inc. has a 52-week low of $398.50 and a 52-week high of $583.39. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42. The company has a market capitalization of $35.58 billion, a price-to-earnings ratio of 41.89, a price-to-earnings-growth ratio of 3.76 and a beta of 1.37. The firm has a 50-day moving average of $447.62 and a 200-day moving average of $475.46.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its earnings results on Thursday, October 31st. The company reported $2.80 EPS for the quarter, beating the consensus estimate of $2.69 by $0.11. The company had revenue of $975.50 million for the quarter, compared to analyst estimates of $980.32 million. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The firm's quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter last year, the firm earned $2.53 EPS. Equities analysts expect that IDEXX Laboratories, Inc. will post 10.43 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on IDXX shares. JPMorgan Chase & Co. lowered their price target on IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating on the stock in a research report on Friday, October 11th. Piper Sandler reiterated a "neutral" rating and issued a $435.00 price objective (down from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. Leerink Partners initiated coverage on IDEXX Laboratories in a research note on Monday. They issued an "outperform" rating and a $500.00 price objective on the stock. Stifel Nicolaus reduced their price objective on IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating on the stock in a report on Thursday, October 10th. Finally, Leerink Partnrs upgraded shares of IDEXX Laboratories to a "strong-buy" rating in a research report on Monday. Two analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $546.56.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.